Pharmacotherapeutic approaches of Parkinson's disease

International Journal of Pharmacology

Volumn 6, Issue 5, 2010, Pages 584-590

  Ansari, J A ^a   Siraj, A ^a   Inamdar, N N ^b  

^a HAMDARD UNIVERSITY   (India)

^b Allana College of Pharmacy   (India)

Author keywords

Levodopa; Parkinson disease; Pharmacotherapy

Indexed keywords

AMANTADINE; ANTIHISTAMINIC AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LAZABEMIDE; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SCOPOLAMINE; SELEGILINE; TOLCAPONE; UBIDECARENONE;

ARTICLE; BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DISEASE COURSE; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; HALLUCINATION; HUMAN; LIVER TOXICITY; MENTAL DISEASE; MOTOR CONTROL; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; NEUROSURGERY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 77955670629     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2010.584.590     Document Type: Article

References (42)

1. Antonini, A. and P. Barone, 2008. Dopamine agonistbased strategies in the treatment of Parkinson's disease. Neurol. Sci., 29: 371-374.
2. Committee on Safety of Medicines, 2002. Fibrotic reactions with pergolide and other ergot derived dopamine receptor agonists. Curr. Probl. Pharmacovigilance, 28: 3-3.
3. Cotzias, G.C., M.H.V. Woert and L.M. Schiffer, 1967. Aromatic amino acids and modification of Parkinsonism. N. Engl. J. Med., 276: 374-379.
4. Crosby, N.J., K.H.O. Deane and C.E. Clarke, 2004. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst. Rev., 10.1002/14651858.CD003467
5. Deane, K., S. Spieker and C.E. Clarke, 2004. Catechol-Omethytransferase Inhibitors Versus Active Comparators for Levodopa-Induced Complications in Parkinson's Disease. John Wiley and Sons, Ltd., Chichester, UK.
6. Deane, K.H.O., S. Spieker and C.E. Clarke, 2005. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev.
7. Dewey, Jr. R.B., M.D. Maraganore, J.E. Ahlskog and J.Y. Matsumoto, 1996. Intranasal apomorphine rescue therapy for parkinsonian off periods. Clin. Neuropharmacol., 19: 193-201.
8. Dewey, Jr. R.B., M.D. Maraganore, J.E. Ahlskog and J.Y. Matsumoto, 1998. A double-blind, placebo controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. Mov. Disord., 13: 782-787.
9. Ford-Martin, P., 2000. The Gale Encyclopedia of Alternative Medicine. Gale Group, Michgan.
10. Frankel, J.P., A.J. Lees, P.A. Kempster and G.M. Stern, 1990. Subcutaneous apomorphine in the treatment of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 53: 96-101.
11. Greene, P.E. and S. Fahn, 2002. Status of fetal tissue transplantation for the treatment of advanced Parkinson disease. Neurosurg Focus, 13: 5-5.
12. Hirsch, M.A., 2009. Muscle strength in Parkinson's disease. Commentary on Pang and Mak. J. Rehabil. Med., 41: 291-292.
13. Hutton, J.T., L.V. Merman, T.N. Chase, J.L. Juncos and W.C. Koller et al., 2001. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease withN-0923TDS: A doubleblind, placebo-controlled study. Mov. Disord., 16: 459-463.
14. Inamdar, N.N., D.K. Arulmozhi, A. Tandon and S.L. Bodhankar, 2007. Parkinson's disease: Genetics and beyond. Curr. Neuropharmacol., 5: 99-113.
15. Ives, N, R. Stowe, J. Marro, C. Counsell and A. Macleod et al, 2004. Monoamine oxidase type B inhibitors in early Parkinson's disease: Meta-analysis of 17 randomised trials involving 3525 patients. BMJ., 329: 593-593.
16. Jankovic, J., 2008. Parkinson's disease: Clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry, 79: 368-376.
17. Jenner, P., G. Al-Barghouthy, L. Smith, M. Kuoppamaki, M. Jackson and S. Rose, 2002. Entacapone combined with L-DOPA enhances antiparkinsonian activity and avoids dyskinesiain the MPTP-treated primate model of Parkinson's disease. Mov. Disord., 17: 57-58.
18. Katzenschlager, R., C. Sampaio, J. Costa and A. Lees, 2004. Ochrane Library. John Wiley and Sons, Ltd., Chichester, UK.
19. Koller, W., A. Lees, M. Doder and M. Hely, 2001. Tolcapone/Pergolide study group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov. Disord., 16: 858-866.
20. Manson, A., K. Turner and A. Lees, 2002. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients. Mov. Disord, 17: 1235-1241.
21. Merman, L., M. Gillespie, C. Farmer, F. Bibbiani and S. Konitsiotis et al, 2001. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin. Neuropharmacol., 24: 163-169.
22. Movement Disorders Society Task Force, 2002. Management of Parkinson's disease: An evidencebased review. Mov. Disord., 17: 1-166.
23. Myllyla, V., T. Miettinen, H. Heikkinen and K. Reinikainen, 2003. New triple combination of levodopa/carbidopa/entacapone is a preferred treatment in patients with Parkinson's disease. Neurology, 60: 289-289.
24. Piccini, P. and AL. Whone, 2004. Functional brain imaging in the differential diagnosis of Parkinson's disease. LancetNeurol., 3: 284-290.
25. Quinn, N, P. Cntchley, D. Parkes and CD. Marsden, 1986. When should levodopa be started?. Lancet, 2: 985-986.
26. Rabey, J.M., I. Sagi, E. Huberman, E. Melamed and A. Korczyn et al, 2000. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa. Clin. Neuropharmacol., 23: 324-330.
27. Rajput, A.H., W. Stern and W.H. Laverty, 1984. Chronic low-dose levodopa therapy in Parkinson's disease: An argument for delaying levodopa therapy. Neurology, 34: 991-996.
28. Ramaker, C. and J. van Hilten, 2004. Bromocriptine/Levodopa Combined Versus Levodopa Alone for Early Parkinson's Disease (Cochrane Review). John Wiley and Sons, Ltd., Chichester, UK.
29. Rascol, O., D. Brooks, E. Melamed, W. Oertel and W. Poewe et al, 2003. A comparative randomized study of rasagiline versusplacebo or entacapone as adjuncts to levodopa in Parkinson's disease patients with motor fluctuations (the LARGO study). Eur. J. Neurol, 10: 234-244.
30. Ravina, B.M., S.C. Fagan, RG. Hart, C.A. Hovinga, D.D. Murphy, T.M. Dawson and J.R. Marler, 2003. Neuroprotective agents for clinical trials in Parkinson's disease. Neurology, 60: 1234-1240.
31. Schwab, R.S., D.C. Poskanzerand, A.C. Jr. England, 1972. Youn Anticholinergics for Symptomatic Management of Parkinson's Disease (Cochrane Review). In: Amantadine in Parkinson's Disease: Review of More than Two Years Experience, Cg, R.R. (Ed.). Japan Automobile Manufacturers Association, Canada, pp: 792-795.
32. Sechi, G., M.G. Deledda, G. Bua, W.M. Satta, G.A. Deiana, G.M. Pes and G. Rosati, 1996. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 20: 1159-1170.
33. Shellenberger, M.K., A. Clarke and D.S. Zydis, 2000. Selegiline reduces off time and improves symptoms in patients with Parkinson's disease. Mov. Disord., 15: 116-117.
34. Shults, C.W., D. Oakes, K. Kieburtz, M.F. Beal and R. Haas et al., 2002. Parkinson study Group. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch. Neurol, 59: 1541-1550.
35. Silverdale, M., S. Fox, A. Crossman and J. Brotchie, 2003. Potential nondopaminergic drugs for Parkinson's disease. Adv. Neurol, 91: 273-291.
36. Smith, L., M. Jackson, M. Hansard, E. Maratos and P. Jenner, 2003. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets. Mov. Disord., 18: 487-495.
37. Starr, P.A., J.L. Vitek and R.A. Bakay, 1998. Ablative surgery and deep brain stimulation for Parkinson's disease. Neurosurgery, 43: 989-1013.
38. Thomas, A., D. Iacono, A. Luciano, K. Armellino, A. Di Iorio and M. Onofrj, 2004. Duration ofamantadine benefit on dyskinesia of severe Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 75: 141-143.
39. Tolcapone Study Group, 1999. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov. Disord., 14: 38-44.
40. Tyne, H., J. Parsons, A. Sinnott, S. Fox, M. Steiger and N. Fletcher, 2002. A 10 year retrospective audit of longterm apomorphine use in Parkinson's disease. Mov. Disord., 17: 75-76.
41. Wright W.A., B.A. Evanoff, M. Lian, S.R. Cnswell and B.A. Racette, 2010. Geographic and ethnic variation in parkinson disease: A population-based study of US medicare beneficiaries. Neuroepidemiology, 34: 143-151.
42. Yousefi, B., V. Tadibi, A.F. Khoei and A. Montazen, 2009. Exercise therapy, quality of life and activities of daily living in patients with Parkinson disease: A small scale quasi-randomised trial. Trials, 10: 67-67.